Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Galectin Therapeutics stock | $3.37

Learn how to easily invest in Galectin Therapeutics stock.

Galectin Therapeutics Inc is a biotechnology business based in the US. Galectin Therapeutics shares (GALT) are listed on the NASDAQ and all prices are listed in US Dollars. Galectin Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Galectin Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GALT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Galectin Therapeutics stock price (NASDAQ: GALT)

Use our graph to track the performance of GALT stocks over time.

Galectin Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$3.37
52-week range$1.91 - $5.70
50-day moving average $3.77
200-day moving average $3.47
Wall St. target price$14.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.50

Buy Galectin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galectin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galectin Therapeutics price performance over time

Historical closes compared with the close of $3.37 from 2021-10-15

1 week (2021-10-08) -3.16%
1 month (2021-09-17) -17.00%
3 months (2021-07-16) 26.69%
6 months (2021-04-16) 53.88%
1 year (2020-10-16) 20.79%
2 years (2019-10-17) -15.75%
3 years (2018-10-17) 4.99
5 years (2016-10-17) 296.47%

Galectin Therapeutics financials

Gross profit TTM $0
Return on assets TTM -47.29%
Return on equity TTM -105.61%
Profit margin 0%
Book value $0.25
Market capitalisation $199.8 million

TTM: trailing 12 months

Shorting Galectin Therapeutics shares

There are currently 2.4 million Galectin Therapeutics shares held short by investors – that's known as Galectin Therapeutics's "short interest". This figure is 14.1% down from 2.7 million last month.

There are a few different ways that this level of interest in shorting Galectin Therapeutics shares can be evaluated.

Galectin Therapeutics's "short interest ratio" (SIR)

Galectin Therapeutics's "short interest ratio" (SIR) is the quantity of Galectin Therapeutics shares currently shorted divided by the average quantity of Galectin Therapeutics shares traded daily (recently around 362939.29121726). Galectin Therapeutics's SIR currently stands at 6.49. In other words for every 100,000 Galectin Therapeutics shares traded daily on the market, roughly 6490 shares are currently held short.

However Galectin Therapeutics's short interest can also be evaluated against the total number of Galectin Therapeutics shares, or, against the total number of tradable Galectin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galectin Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Galectin Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0541% of the tradable shares (for every 100,000 tradable Galectin Therapeutics shares, roughly 54 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Galectin Therapeutics.

Find out more about how you can short Galectin Therapeutics stock.

Galectin Therapeutics share dividends

We're not expecting Galectin Therapeutics to pay a dividend over the next 12 months.

Have Galectin Therapeutics's shares ever split?

Galectin Therapeutics's shares were split on a 1:6 basis on 22 March 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galectin Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Galectin Therapeutics shares which in turn could have impacted Galectin Therapeutics's share price.

Galectin Therapeutics share price volatility

Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.91 up to $5.7. A popular way to gauge a stock's volatility is its "beta".

GALT.US volatility(beta: 2.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galectin Therapeutics's is 2.2651. This would suggest that Galectin Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galectin Therapeutics overview

Galectin Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc. , to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Galectin Therapeutics is owned by insiders or institutions?
Currently 27.936% of Galectin Therapeutics shares are held by insiders and 13.1% by institutions.
How many people work for Galectin Therapeutics?
Latest data suggests 6 work at Galectin Therapeutics.
When does the fiscal year end for Galectin Therapeutics?
Galectin Therapeutics's fiscal year ends in December.
Where is Galectin Therapeutics based?
Galectin Therapeutics's address is: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
What is Galectin Therapeutics's ISIN number?
Galectin Therapeutics's international securities identification number is: US3632252025
What is Galectin Therapeutics's CUSIP number?
Galectin Therapeutics's Committee on Uniform Securities Identification Procedures number is: 363225103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site